Loading…
Effect of Therapeutic Inhibition of TNF on Circulating Endothelial Progenitor Cells in Patients with Rheumatoid Arthritis
Endothelial dysfunction has been detected in RA patients and seems to be reversed by control of inflammation. Low circulating endothelial progenitor cells (EPCs) have been described in many conditions associated with increased cardiovascular risk, including RA. The aim of this study was to investiga...
Saved in:
Published in: | Mediators of Inflammation 2013-01, Vol.2013 (2013), p.960-967-187 |
---|---|
Main Authors: | , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-a644t-898777704daef46a39548af7d14bcab3a059d959446f1be2faea90479845c9bc3 |
---|---|
cites | cdi_FETCH-LOGICAL-a644t-898777704daef46a39548af7d14bcab3a059d959446f1be2faea90479845c9bc3 |
container_end_page | 967-187 |
container_issue | 2013 |
container_start_page | 960 |
container_title | Mediators of Inflammation |
container_volume | 2013 |
creator | Spinelli, F. R. Metere, A. Barbati, C. Pierdominici, M. Iannuccelli, C. Lucchino, B. Ciciarello, F. Agati, Luciano Valesini, Guido Di Franco, Manuela |
description | Endothelial dysfunction has been detected in RA patients and seems to be reversed by control of inflammation. Low circulating endothelial progenitor cells (EPCs) have been described in many conditions associated with increased cardiovascular risk, including RA. The aim of this study was to investigate the effect of inhibition of TNF on EPCs in RA patients. Seventeen patients with moderate-severe RA and 12 sex and age-matched controls were evaluated. Endothelial biomarkers were tested at baseline and after 3 months. EPCs were identified from peripheral blood mononuclear cells by cytofluorimetry using anti-CD34 and anti-vascular endothelial growth factor-receptor 2. Asymmetric dimethylarginine (ADMA) was tested by ELISA and flow-mediated dilatation (FMD) by ultrasonography. Circulating EPCs were significantly lower in RA patients than in controls (P=0.001). After 3 months EPCs increased significantly (P=0.0006) while ADMA levels significantly decreased (P=0.001). An inverse correlation between mean increase in EPCs number and mean decrease of DAS28 after treatment was observed (r=−0.56, P=0.04). EPCs inversely correlated with ADMA (r=−0.41, P=0.022). No improvement of FMD was detected. Short-term treatment with anti-TNF was able to increase circulating EPCs concurrently with a proportional decrease of disease activity suggesting that therapeutic intervention aimed at suppressing the inflammatory process might positively affect the endothelial function. |
doi_str_mv | 10.1155/2013/537539 |
format | article |
fullrecord | <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_ba753b3fb1f346389bf5843ef378226c</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A377997293</galeid><airiti_id>P20160527003_201312_201703020022_201703020022_960_967_187</airiti_id><doaj_id>oai_doaj_org_article_ba753b3fb1f346389bf5843ef378226c</doaj_id><sourcerecordid>A377997293</sourcerecordid><originalsourceid>FETCH-LOGICAL-a644t-898777704daef46a39548af7d14bcab3a059d959446f1be2faea90479845c9bc3</originalsourceid><addsrcrecordid>eNqFks2L1DAYh4so7rh68qwUvIgyu_n-uAjDMKsDiw6ynkPaJtMMnWQ3TV32vzedroMjgi0lbd4nD3nTX1G8huACQkovEYD4kmJOsXxSzCBhbA4Fg0-LGZAMzSWm8Kx40fc7AAAlRDwvzhBBCHEoZ8XDylpTpzLY8qY1Ud-aIbm6XPvWVS654A-Vr1dlflu6WA-dTs5vy5VvQmpN53RXbmLYGu9SiOXSdF1fOl9uMmZ86st7l9rye2uGvU7BNeUipjZmc_-yeGZ115tXj-N58eNqdbP8Mr_-9nm9XFzPNSMkzYUUPF-ANNpYwjSWlAhteQNJVesKa0BlI6kkhFlYGWS10RIQLgWhtaxqfF6sJ28T9E7dRrfX8UEF7dRhIsSt0jH33BlV6XyIFbYVtJgwLGRlqSDYWMwFQmx0fZpct0O1N02dO4y6O5GeVrxr1Tb8VFhAABjIgvePghjuBtMntXd9nQ9NexOGXkFCBQU0wxl9N6FbnbfmvA3ZWI-4WmDOpeRI4kxd_IPKd2P2rg7eWJfnTxZ8nBbUMfR9NPa4ewjUmCc15klNecr02z8bPrK_A5SBDxPQOt_oe_cf25sJNhkxVh_h_LsYHlveTHXtxoioXRiiz9lQm2xhgCKez-VghGgcOMAAAYD--pAM5IcrKDj-BUFk8To</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1458505100</pqid></control><display><type>article</type><title>Effect of Therapeutic Inhibition of TNF on Circulating Endothelial Progenitor Cells in Patients with Rheumatoid Arthritis</title><source>PubMed (Medline)</source><source>Wiley-Blackwell Open Access Collection</source><creator>Spinelli, F. R. ; Metere, A. ; Barbati, C. ; Pierdominici, M. ; Iannuccelli, C. ; Lucchino, B. ; Ciciarello, F. ; Agati, Luciano ; Valesini, Guido ; Di Franco, Manuela</creator><contributor>Putterman, Chaim</contributor><creatorcontrib>Spinelli, F. R. ; Metere, A. ; Barbati, C. ; Pierdominici, M. ; Iannuccelli, C. ; Lucchino, B. ; Ciciarello, F. ; Agati, Luciano ; Valesini, Guido ; Di Franco, Manuela ; Putterman, Chaim</creatorcontrib><description>Endothelial dysfunction has been detected in RA patients and seems to be reversed by control of inflammation. Low circulating endothelial progenitor cells (EPCs) have been described in many conditions associated with increased cardiovascular risk, including RA. The aim of this study was to investigate the effect of inhibition of TNF on EPCs in RA patients. Seventeen patients with moderate-severe RA and 12 sex and age-matched controls were evaluated. Endothelial biomarkers were tested at baseline and after 3 months. EPCs were identified from peripheral blood mononuclear cells by cytofluorimetry using anti-CD34 and anti-vascular endothelial growth factor-receptor 2. Asymmetric dimethylarginine (ADMA) was tested by ELISA and flow-mediated dilatation (FMD) by ultrasonography. Circulating EPCs were significantly lower in RA patients than in controls (P=0.001). After 3 months EPCs increased significantly (P=0.0006) while ADMA levels significantly decreased (P=0.001). An inverse correlation between mean increase in EPCs number and mean decrease of DAS28 after treatment was observed (r=−0.56, P=0.04). EPCs inversely correlated with ADMA (r=−0.41, P=0.022). No improvement of FMD was detected. Short-term treatment with anti-TNF was able to increase circulating EPCs concurrently with a proportional decrease of disease activity suggesting that therapeutic intervention aimed at suppressing the inflammatory process might positively affect the endothelial function.</description><identifier>ISSN: 0962-9351</identifier><identifier>EISSN: 1466-1861</identifier><identifier>DOI: 10.1155/2013/537539</identifier><identifier>PMID: 24222719</identifier><language>eng</language><publisher>Cairo, Egypt: Hindawi Limiteds</publisher><subject>Adalimumab ; Adult ; Aged ; Antibodies, Monoclonal, Humanized - therapeutic use ; Antigens, CD34 - metabolism ; Arginine - analogs & derivatives ; Arginine - chemistry ; Arthritis, Rheumatoid - blood ; Arthritis, Rheumatoid - drug therapy ; Biomarkers - metabolism ; Case-Control Studies ; Endothelial Cells - cytology ; Enzyme-Linked Immunosorbent Assay ; Etanercept ; Female ; Flow Cytometry ; Health aspects ; Humans ; Immunoglobulin G - therapeutic use ; Inflammation ; Leukocytes, Mononuclear - cytology ; Male ; Middle Aged ; Physiological aspects ; Receptors, Tumor Necrosis Factor - therapeutic use ; Rheumatoid arthritis ; Stem Cells - cytology ; Tumor necrosis factor ; Tumor Necrosis Factor-alpha - antagonists & inhibitors ; Ultrasonography, Doppler ; Vascular Endothelial Growth Factor Receptor-2 - metabolism</subject><ispartof>Mediators of Inflammation, 2013-01, Vol.2013 (2013), p.960-967-187</ispartof><rights>Copyright © 2013 F. R. Spinelli et al.</rights><rights>COPYRIGHT 2013 John Wiley & Sons, Inc.</rights><rights>Copyright © 2013 F. R. Spinelli et al. 2013</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a644t-898777704daef46a39548af7d14bcab3a059d959446f1be2faea90479845c9bc3</citedby><cites>FETCH-LOGICAL-a644t-898777704daef46a39548af7d14bcab3a059d959446f1be2faea90479845c9bc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3810060/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3810060/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,725,778,782,883,27911,27912,53778,53780</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24222719$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Putterman, Chaim</contributor><creatorcontrib>Spinelli, F. R.</creatorcontrib><creatorcontrib>Metere, A.</creatorcontrib><creatorcontrib>Barbati, C.</creatorcontrib><creatorcontrib>Pierdominici, M.</creatorcontrib><creatorcontrib>Iannuccelli, C.</creatorcontrib><creatorcontrib>Lucchino, B.</creatorcontrib><creatorcontrib>Ciciarello, F.</creatorcontrib><creatorcontrib>Agati, Luciano</creatorcontrib><creatorcontrib>Valesini, Guido</creatorcontrib><creatorcontrib>Di Franco, Manuela</creatorcontrib><title>Effect of Therapeutic Inhibition of TNF on Circulating Endothelial Progenitor Cells in Patients with Rheumatoid Arthritis</title><title>Mediators of Inflammation</title><addtitle>Mediators Inflamm</addtitle><description>Endothelial dysfunction has been detected in RA patients and seems to be reversed by control of inflammation. Low circulating endothelial progenitor cells (EPCs) have been described in many conditions associated with increased cardiovascular risk, including RA. The aim of this study was to investigate the effect of inhibition of TNF on EPCs in RA patients. Seventeen patients with moderate-severe RA and 12 sex and age-matched controls were evaluated. Endothelial biomarkers were tested at baseline and after 3 months. EPCs were identified from peripheral blood mononuclear cells by cytofluorimetry using anti-CD34 and anti-vascular endothelial growth factor-receptor 2. Asymmetric dimethylarginine (ADMA) was tested by ELISA and flow-mediated dilatation (FMD) by ultrasonography. Circulating EPCs were significantly lower in RA patients than in controls (P=0.001). After 3 months EPCs increased significantly (P=0.0006) while ADMA levels significantly decreased (P=0.001). An inverse correlation between mean increase in EPCs number and mean decrease of DAS28 after treatment was observed (r=−0.56, P=0.04). EPCs inversely correlated with ADMA (r=−0.41, P=0.022). No improvement of FMD was detected. Short-term treatment with anti-TNF was able to increase circulating EPCs concurrently with a proportional decrease of disease activity suggesting that therapeutic intervention aimed at suppressing the inflammatory process might positively affect the endothelial function.</description><subject>Adalimumab</subject><subject>Adult</subject><subject>Aged</subject><subject>Antibodies, Monoclonal, Humanized - therapeutic use</subject><subject>Antigens, CD34 - metabolism</subject><subject>Arginine - analogs & derivatives</subject><subject>Arginine - chemistry</subject><subject>Arthritis, Rheumatoid - blood</subject><subject>Arthritis, Rheumatoid - drug therapy</subject><subject>Biomarkers - metabolism</subject><subject>Case-Control Studies</subject><subject>Endothelial Cells - cytology</subject><subject>Enzyme-Linked Immunosorbent Assay</subject><subject>Etanercept</subject><subject>Female</subject><subject>Flow Cytometry</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Immunoglobulin G - therapeutic use</subject><subject>Inflammation</subject><subject>Leukocytes, Mononuclear - cytology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Physiological aspects</subject><subject>Receptors, Tumor Necrosis Factor - therapeutic use</subject><subject>Rheumatoid arthritis</subject><subject>Stem Cells - cytology</subject><subject>Tumor necrosis factor</subject><subject>Tumor Necrosis Factor-alpha - antagonists & inhibitors</subject><subject>Ultrasonography, Doppler</subject><subject>Vascular Endothelial Growth Factor Receptor-2 - metabolism</subject><issn>0962-9351</issn><issn>1466-1861</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNqFks2L1DAYh4so7rh68qwUvIgyu_n-uAjDMKsDiw6ynkPaJtMMnWQ3TV32vzedroMjgi0lbd4nD3nTX1G8huACQkovEYD4kmJOsXxSzCBhbA4Fg0-LGZAMzSWm8Kx40fc7AAAlRDwvzhBBCHEoZ8XDylpTpzLY8qY1Ud-aIbm6XPvWVS654A-Vr1dlflu6WA-dTs5vy5VvQmpN53RXbmLYGu9SiOXSdF1fOl9uMmZ86st7l9rye2uGvU7BNeUipjZmc_-yeGZ115tXj-N58eNqdbP8Mr_-9nm9XFzPNSMkzYUUPF-ANNpYwjSWlAhteQNJVesKa0BlI6kkhFlYGWS10RIQLgWhtaxqfF6sJ28T9E7dRrfX8UEF7dRhIsSt0jH33BlV6XyIFbYVtJgwLGRlqSDYWMwFQmx0fZpct0O1N02dO4y6O5GeVrxr1Tb8VFhAABjIgvePghjuBtMntXd9nQ9NexOGXkFCBQU0wxl9N6FbnbfmvA3ZWI-4WmDOpeRI4kxd_IPKd2P2rg7eWJfnTxZ8nBbUMfR9NPa4ewjUmCc15klNecr02z8bPrK_A5SBDxPQOt_oe_cf25sJNhkxVh_h_LsYHlveTHXtxoioXRiiz9lQm2xhgCKez-VghGgcOMAAAYD--pAM5IcrKDj-BUFk8To</recordid><startdate>20130101</startdate><enddate>20130101</enddate><creator>Spinelli, F. R.</creator><creator>Metere, A.</creator><creator>Barbati, C.</creator><creator>Pierdominici, M.</creator><creator>Iannuccelli, C.</creator><creator>Lucchino, B.</creator><creator>Ciciarello, F.</creator><creator>Agati, Luciano</creator><creator>Valesini, Guido</creator><creator>Di Franco, Manuela</creator><general>Hindawi Limiteds</general><general>Hindawi Puplishing Corporation</general><general>Hindawi Publishing Corporation</general><general>John Wiley & Sons, Inc</general><general>Hindawi Limited</general><scope>188</scope><scope>ADJCN</scope><scope>AHFXO</scope><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20130101</creationdate><title>Effect of Therapeutic Inhibition of TNF on Circulating Endothelial Progenitor Cells in Patients with Rheumatoid Arthritis</title><author>Spinelli, F. R. ; Metere, A. ; Barbati, C. ; Pierdominici, M. ; Iannuccelli, C. ; Lucchino, B. ; Ciciarello, F. ; Agati, Luciano ; Valesini, Guido ; Di Franco, Manuela</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a644t-898777704daef46a39548af7d14bcab3a059d959446f1be2faea90479845c9bc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adalimumab</topic><topic>Adult</topic><topic>Aged</topic><topic>Antibodies, Monoclonal, Humanized - therapeutic use</topic><topic>Antigens, CD34 - metabolism</topic><topic>Arginine - analogs & derivatives</topic><topic>Arginine - chemistry</topic><topic>Arthritis, Rheumatoid - blood</topic><topic>Arthritis, Rheumatoid - drug therapy</topic><topic>Biomarkers - metabolism</topic><topic>Case-Control Studies</topic><topic>Endothelial Cells - cytology</topic><topic>Enzyme-Linked Immunosorbent Assay</topic><topic>Etanercept</topic><topic>Female</topic><topic>Flow Cytometry</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Immunoglobulin G - therapeutic use</topic><topic>Inflammation</topic><topic>Leukocytes, Mononuclear - cytology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Physiological aspects</topic><topic>Receptors, Tumor Necrosis Factor - therapeutic use</topic><topic>Rheumatoid arthritis</topic><topic>Stem Cells - cytology</topic><topic>Tumor necrosis factor</topic><topic>Tumor Necrosis Factor-alpha - antagonists & inhibitors</topic><topic>Ultrasonography, Doppler</topic><topic>Vascular Endothelial Growth Factor Receptor-2 - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Spinelli, F. R.</creatorcontrib><creatorcontrib>Metere, A.</creatorcontrib><creatorcontrib>Barbati, C.</creatorcontrib><creatorcontrib>Pierdominici, M.</creatorcontrib><creatorcontrib>Iannuccelli, C.</creatorcontrib><creatorcontrib>Lucchino, B.</creatorcontrib><creatorcontrib>Ciciarello, F.</creatorcontrib><creatorcontrib>Agati, Luciano</creatorcontrib><creatorcontrib>Valesini, Guido</creatorcontrib><creatorcontrib>Di Franco, Manuela</creatorcontrib><collection>Airiti Library</collection><collection>الدوريات العلمية والإحصائية - e-Marefa Academic and Statistical Periodicals</collection><collection>معرفة - المحتوى العربي الأكاديمي المتكامل - e-Marefa Academic Complete</collection><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Mediators of Inflammation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Spinelli, F. R.</au><au>Metere, A.</au><au>Barbati, C.</au><au>Pierdominici, M.</au><au>Iannuccelli, C.</au><au>Lucchino, B.</au><au>Ciciarello, F.</au><au>Agati, Luciano</au><au>Valesini, Guido</au><au>Di Franco, Manuela</au><au>Putterman, Chaim</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of Therapeutic Inhibition of TNF on Circulating Endothelial Progenitor Cells in Patients with Rheumatoid Arthritis</atitle><jtitle>Mediators of Inflammation</jtitle><addtitle>Mediators Inflamm</addtitle><date>2013-01-01</date><risdate>2013</risdate><volume>2013</volume><issue>2013</issue><spage>960</spage><epage>967-187</epage><pages>960-967-187</pages><issn>0962-9351</issn><eissn>1466-1861</eissn><abstract>Endothelial dysfunction has been detected in RA patients and seems to be reversed by control of inflammation. Low circulating endothelial progenitor cells (EPCs) have been described in many conditions associated with increased cardiovascular risk, including RA. The aim of this study was to investigate the effect of inhibition of TNF on EPCs in RA patients. Seventeen patients with moderate-severe RA and 12 sex and age-matched controls were evaluated. Endothelial biomarkers were tested at baseline and after 3 months. EPCs were identified from peripheral blood mononuclear cells by cytofluorimetry using anti-CD34 and anti-vascular endothelial growth factor-receptor 2. Asymmetric dimethylarginine (ADMA) was tested by ELISA and flow-mediated dilatation (FMD) by ultrasonography. Circulating EPCs were significantly lower in RA patients than in controls (P=0.001). After 3 months EPCs increased significantly (P=0.0006) while ADMA levels significantly decreased (P=0.001). An inverse correlation between mean increase in EPCs number and mean decrease of DAS28 after treatment was observed (r=−0.56, P=0.04). EPCs inversely correlated with ADMA (r=−0.41, P=0.022). No improvement of FMD was detected. Short-term treatment with anti-TNF was able to increase circulating EPCs concurrently with a proportional decrease of disease activity suggesting that therapeutic intervention aimed at suppressing the inflammatory process might positively affect the endothelial function.</abstract><cop>Cairo, Egypt</cop><pub>Hindawi Limiteds</pub><pmid>24222719</pmid><doi>10.1155/2013/537539</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0962-9351 |
ispartof | Mediators of Inflammation, 2013-01, Vol.2013 (2013), p.960-967-187 |
issn | 0962-9351 1466-1861 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_ba753b3fb1f346389bf5843ef378226c |
source | PubMed (Medline); Wiley-Blackwell Open Access Collection |
subjects | Adalimumab Adult Aged Antibodies, Monoclonal, Humanized - therapeutic use Antigens, CD34 - metabolism Arginine - analogs & derivatives Arginine - chemistry Arthritis, Rheumatoid - blood Arthritis, Rheumatoid - drug therapy Biomarkers - metabolism Case-Control Studies Endothelial Cells - cytology Enzyme-Linked Immunosorbent Assay Etanercept Female Flow Cytometry Health aspects Humans Immunoglobulin G - therapeutic use Inflammation Leukocytes, Mononuclear - cytology Male Middle Aged Physiological aspects Receptors, Tumor Necrosis Factor - therapeutic use Rheumatoid arthritis Stem Cells - cytology Tumor necrosis factor Tumor Necrosis Factor-alpha - antagonists & inhibitors Ultrasonography, Doppler Vascular Endothelial Growth Factor Receptor-2 - metabolism |
title | Effect of Therapeutic Inhibition of TNF on Circulating Endothelial Progenitor Cells in Patients with Rheumatoid Arthritis |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T20%3A38%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20Therapeutic%20Inhibition%20of%20TNF%20on%20Circulating%20Endothelial%20Progenitor%20Cells%20in%20Patients%20with%20Rheumatoid%20Arthritis&rft.jtitle=Mediators%20of%20Inflammation&rft.au=Spinelli,%20F.%20R.&rft.date=2013-01-01&rft.volume=2013&rft.issue=2013&rft.spage=960&rft.epage=967-187&rft.pages=960-967-187&rft.issn=0962-9351&rft.eissn=1466-1861&rft_id=info:doi/10.1155/2013/537539&rft_dat=%3Cgale_doaj_%3EA377997293%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-a644t-898777704daef46a39548af7d14bcab3a059d959446f1be2faea90479845c9bc3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1458505100&rft_id=info:pmid/24222719&rft_galeid=A377997293&rft_airiti_id=P20160527003_201312_201703020022_201703020022_960_967_187&rfr_iscdi=true |